The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / New Paradigm Investing


Subject:  Re: exel call Date:  11/8/2012  10:24 AM
Author:  TMFCandyMountain Number:  65424 of 78482

Short timelines - The phase III trial will start next month with progression-free survival as the primary endpoint. Enrollment should be very quick, given Roche's experience in the indication (Zelboraf was the 1st approved drug for BRAF-mutated melanoma) and the fact that melanoma patients are routinely screened for BRAF status and treated with Zelboraf. Top line results could be available in mid-2014, and Roche expects to submit the combination for approval in 2014.

Don't know where Ohad got his timeline info. Maybe an educated guess?

Roche Q3 slide deck, slide 48:
Copyright 1996-2016 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us